Lexicon Reports Q1 2026 Earnings: Revenue Surpasses $21M Driven by Milestone Payments
Lexicon (LXRX) reported first-quarter earnings for 2026 with total revenue of $21.1 million, primarily driven by two milestone payments from Novo Nordisk and INPEFA sales. The company also noted a significant reduction in R&D expenses due to the completion of trials and licensing agreements.

Topics: cash reserves clinical trials debt refinancing net loss R&D expenses revenue SG&A expenses